We identified variation near SRD5A2, the gene product being a target of antiandrogen drugs for the treatment of male-pattern baldness and benign prostatic hyperplasia11, as associated with eight steroid metabolites of steroid hormone biosynthesis, including six androgen metabolites (Fig. 5 and Supplementary Table 7). This evidence concerns the gene SRD5A2 and androgenetic alopecia.